January 25, 2021

Jennifer Forrester, MD, of the UC Division of Infectious Diseases is one of the statewide experts featured in a spot from the Ohio Department of Health on how society navigates the road back from the COVID-19 pandemic.

January 13, 2021

Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases is one of the experts featured in a Cincinnati.com article on COVID-19 vaccination cards.

February 1, 2021

Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases, was used by Local12 as an expert source on the news of the efficacy of the Johnson & Johnson COVID-19 vaccine.

January 5, 2021

Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases was interviewed by WLWT-TV for a story on the FDA considering distributing half doses of the Moderna COVID-19 vaccine to people between the ages of 18-55 in order to stretch the supply of the vaccine.

February 17, 2021

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was interviewed by a reporter from the San Fernando Valley Business Journal about California lifting the restrictions on commercial outdoor dining.

February 10, 2021

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine, was interviewed by FOX19 for a story on how the Johnson & Johnson COVID-19 vaccine was still effective despite its efficacy rate of 66%.

March 9, 2021

Spectrum News interviewed Shaina Horner of the UC Division of Infectious Diseases about her role of using her established relationships in the local Latinx community to increase that population's involvement in the Modera COVID-19 vaccine trial at UC.

February 12, 2021

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine, was interviewed by a reporter writing a story on vaccine passports. Fichtenbaum doesn't see the benefit to them.

March 15, 2021

Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases, was featured as an expert source in a story on Medscape about animal model research showing that a new adjuvant, or ingredient, added to COVID-19 vaccines has shown promise for its ability to deliver the vaccine directly into lymph nodes.

March 24, 2021

Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was one of the sources quoted in an article for Reuters Health on a study showing that in patients with moderate-severe COVID-19, recombinant super-compound interferon plus baseline antivirals was associated with a shorter time to clinical improvement than the same regimen using traditional interferon-alpha in an exploratory trial in China. Fichtenbaum said a lot more data and proof is needed before he would use this. And the lack of a control group that got just standard of care is a big weakness of this study.